Cancer Surgery References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. Bird NC, Mangnall D, Majeed AW. Biology of colorectal liver metastases: A review. J SurgOncol. 2006 Jul 1;94(1):68-80.
  2. van der BijGJ, OosterlingSJ, Beelen RH, et al. The perioperative period is an underutilized window of therapeutic opportunity in patients with colorectal cancer. Ann Surg. 2009 May;249(5):727-34.
  3. Wagenaar-Miller RA, Gordon L, Matrisian LM. Matrix metalloproteinases in colorectal cancer: is it worth talking about? Cancer Metastasis Rev. 2004 Jan;23(1-2):119-35.
  4. Ben-Eliyahu S. The promotion of tumor metastasis by surgery and stress: immunological basis and implications for psychoneuroimmunology. Brain Behav Immun. 2003 Feb;17Suppl1S27-S36.
  5. Yamaguchi K, Takagi Y, Aoki S, Futamura M, et al. Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. Ann Surg. 2000 Jul;232(1):58-65.
  6. Da Costa ML, Redmond P, Bouchier-Hayes DJ. The effect of laparotomy and laparoscopy on the establishment of spontaneous tumor metastases. Surgery. 1998 Sep;124(3):516-25.
  7. Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann SurgOncol. 2003 Oct;10(8):972-92.
  8. Demicheli R, Valagussa P, Bonadonna G. Does surgery modify growth kinetics of breast cancer micrometastases? Br J Cancer. 2001 Aug 17;85(4):490-2.
  9. DowdallJF, Winter DC, Andrews E, et al. Soluble interleukin 6 receptor (sIL-6R) mediates colonic tumor cell adherence to the vascular endothelium: a mechanism for metastatic initiation? J Surg Res. 2002 Sep;107(1):1-6.
  10. Raz A, Lotan R. Endogenous galactoside-binding lectins: a new class of functional tumor cell surface molecules related to metastasis. Cancer Metastasis Rev. 1987;6(3):433-52.
  11. Yu LG, Andrews N, Zhao Q, et al. Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion. J Biol Chem. 2007 Jan 5;282(1):773-81.
  12. ten Kate M, HoflandLJ, van GrevensteinWM, et al. Influence of proinflammatory cytokines on the adhesion of human colon carcinoma cells to lung microvascular endothelium. Int J Cancer. 2004 Dec 20;112(6):943-50.
  13. Nangia-Makker P, Hogan V, Honjo Y, et al. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst. 2002 Dec 18;94(24):1854-62.
  14. Pienta KJ, Naik H, Akhtar A, et al. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst. 1995 Mar 1;87(5):348-53.
  15. Platt D, Raz A. Modulation of the lung colonization of B16-F1 melanoma cells by citrus pectin. J Natl Cancer Inst. 1992 Mar 18;84(6):438-42.
  16. Guess BW, Scholz MC, Strum SB, et al. Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study. Prostate Cancer Prostatic Dis. 2003;6(4):301-4.
  17. Azemar M, Hildenbrand B, Haering B, et al. Clinical Benefits in Patients with Advanced Tumors Treated with Modified Citrus Pectin: A Prospective Pilot Study. Clin Med Oncol. 2007:173–80.
  18. Matsumoto S, Imaeda Y, Umemoto S, et al. Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumor cells. Br J Cancer. 2002 Jan 21;86(2):161-7.
  19. Adams WJ, Morris DL. Short-course cimetidine and survival with colorectal cancer. Lancet. 1994 Dec 24;344(8939-8940):1768-9.
  20. HerbermanRB, Ortaldo JR. Natural killer cells: their roles in defenses against disease. Science. 1981 Oct 2;214(4516):24-30.
  21. MccoyJL, Rucker R, Petros JA. Cell-mediated immunity to tumor-associated antigens is a better predictor of survival in early stage breast cancer than stage, grade or lymph node status. Breast Cancer Res Treat. 2000 Apr;60(3):227-34.
  22. Koda K, Saito N, Takiguchi N, et al. Preoperative natural killer cell activity: correlation with distant metastases in curatively research colorectal carcinomas. Int Surg. 1997 Apr;82(2):190-3.
  23. McCulloch PG, MacIntyre A. Effects of surgery on the generation of lymphokine-activated killer cells in patients with breast cancer. Br J Surg. 1993 Aug;80(8):1005-7.
  24. Rosenne E, Shakhar G, Melamed R, et al. Inducing a mode of NK-resistance to suppression by stress and surgery: a potential approach based on low dose of poly I-C to reduce postoperative cancer metastasis. Brain Behav Immun. 2007 May;21(4):395-408.
  25. Ohwada S, Ogawa T, Makita F, et al. Beneficial effects of protein-bound polysaccharide K plus tegafur/uracil in patients with stage II or III colorectal cancer: analysis of immunological parameters. Oncol Rep. 2006 Apr;15(4):861-8.
  26. Fisher M, Yang LX. Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy. Anticancer Res. 2002 May;22(3):1737-54.
  27. Garcia-Lora A, Pedrinaci S, Garrido F. Protein-bound polysaccharide K and interleukin-2 regulate difference nuclear transcription factors in the NKL human natural killer cell line. Cancer ImmunolImmunother. 2001 Jun;50(4):191-8.
  28. Pedrinaci S, Algarra I, Garrido F. Protein-bound polysaccharide (PSK) induces cytotoxic activity in the NKL human natural killer cell line. Int J Clin Lab Res. 1999;29(4):135-40.
  29. Hayakawa K, Mitsuhashi N, Saito Y, et al. Effect of Krestin as adjuvant treatment following radical radiotherapy in non-small cell lung cancer patients. Cancer Detect Prev. 1997;21(1):71-7.
  30. Sakai T, Yamashita Y, Maekawa T, et al. Immunochemotherapy with PSK and fluoropyrimidines improves long-term prognosis for curatively resected colorectal cancer. Cancer BiotherRadiopharm. 2008 Aug;23(4):461-7.
  31. Ohwada S, Ikeya T, Yokomori T, et al. Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study. Br J Cancer. 2004 Mar 8;90(5):1003-10.
  32. Okazaki A, Mitsuhashi N, Yamakawa M, et al. [The effects of PS-K on long-term survival of uterine cervical cancer patients treated with radiation]. Gan No Rinsho. 1986 Feb;32(2):181-5.
  33. Nakazato H, Koike A, Saji S, et al. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet. 1994 May 7;343(8906):1122-6.
  34. Ogoshi K. [Evaluation of immunotherapy with PSK in esophageal cancer]. Gan To Kagaku Ryoho. 1988 Nov;15(11):3143-51.
  35. Toi M, Hattori T, Akagi M, et al. Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-Year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization. Cancer. 1992 Nov 15;70(10):2475-83.
  36. Ishikawa H, Saeki T, Otani T, et al. Aged garlic extract prevents a decline of NK cell number and activity in patients with advanced cancer. J Nutr. 2006 Mar;136(3 Suppl):816S-820S.
  37. Baten A, Ullah A, TomazicVJ, et al. Inositol-phosphate-induced enhancement of natural killer cell activity correlates with tumor suppression. Carcinogenesis. 1989 Sep;10(9):1595-8.
  38. Kuhara T, Yamauchi K, Tamura Y, et al. Oral administration of lactoferrin increases NK cell activity in mice via increased production of IL-18 and type I IFN in the small intestine. J Interferon Cytokine Res. 2006 Jul;26(7):489-99.
  39. KlimbergVS, Kornbluth J, Cao Y, et al. Glutamine suppresses PGE2 synthesis and breast cancer growth. J Surg Res. 1996 Jun;63(1):293-7.
  40. Matsui Y, Uhara J, Satoi S, et al. Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study. J Hepatol. 2002 Jul;37(1):78-86.
  41. Schink M, Troger W, Dabidian A, et al. Mistletoe extract reduces the surgical suppression of natural killer cell activity in cancer patients. a randomized phase III trial. ForschKomplementmed. 2007 Feb;14(1):9-17.
  42. Mels AK, Statius Muller MG, van Leeuwen PA, et al. Immune-stimulating effects of low-dose perioperative recombinant granulocyte-macrophage colony-stimulating factor in patients operated on for primary colorectal carcinoma. Br J Surg. 2001 Apr;88(4):539-44.
  43. Bhandarkar SS, Arbiser JL. Curcumin as an inhibitor of angiogenesis. AdvExp Med Biol. 2007;595:185-95.
  44. Brivio F, Lissoni P, Rovelli F, et al. Effects of IL-2 preoperative immunotherapy on surgery-induced changes in angiogenic regulation and its prevention of VEGF increase and IL-12 decline. Hepatogastroenterology. 2002 Mar-Apr;49(44):385-7.
  45. Mosolits S, Ullenhag G, Mellstedt H. Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. Ann Oncol. 2005 Jun;16(6):847-62.
  46. Choudhury A, Mosolits S, Kokhaei P, et al. Clincial results of vaccine therapy for cancer: learning from history for improving the future. Adv Cancer Res. 2006;95:147-202.
  47. Liang W, Wang H, Sun TM, et al. Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. World J Gastroenterol. 2003 Mar;9(3):495-8.
  48. Ribatti D. History of Research on Tumor Angiogenesis. Springer;2009:9.
  49. Rege TA, Fears CY, Gladson CL. Endogenous inhibitors of angiogenesis in malignant gliomas: nature’s antiangiogenic therapy. NeuroOncol. 2005 Apr;7(2):106-21.
  50. Baum M, Demicheli R, Hrushesky W, et al. Does surgery unfavourably perturb the “natural history” of early breast cancer by accelerating the appearance of distant metastases? Eur J Cancer. 2005 Mar;41(4):508-15.
  51. Folkman J. Fundamental concepts of the angiogenic process. CurrMol Med. 2003 Nov;3(7):643-51.
  52. Pinsolle V, Ravaud A, Baudet J. [Does surgery promote the development of metastasis in melanoma?]. Ann ChirPlastEsthet. 2000 Aug;45(4):485-93.
  53. Raymond E. [Tumor angiogenesis inhibitors: media and scientific aspects]. Presse Med. 1998 Jul 4-11;27(24):1221-4.
  54. Goldfarb Y, Ben-Eliyahu S. Surgery as a risk factor for breast cancer recurrence and metastasis: mediating mechanisms and clinical prophylactic approaches. Breast Dis. 2006-2007;26:99-114.
  55. Zhu BH, Zhan WH, Li ZR, et al. (-)-Epigallocatechin-3-gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis. World J Gastroenterol. 2007 Feb 28;13(8):1162-9.
  56. Yoysungnoen P, Wirachwong P, Bhattarakosol P, et al. Effects of curcumin on tumor angiogenesis and biomarkers, COX-2 and VEGF, in hepatocellular carcinoma cell-implanted nude mice. ClinHemorheolMicrocirc. 2006;34(1-2):109-15.
  57. Binion DG, Otterson MF, Rafiee P. Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut. 2008 Nov;57(11):1509-17.
  58. Guo Y, Wang S, Hoot DR, et al. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones. J NutrBiochem. 2007 Jun;18(6):408-17.
  59. Buchler P, Reber HA, Buchler MW, et al. Antiangiogenic activity of genistein in pancreatic carcinoma cells is mediated by the inhibition of hypoxia-inducible factor-1 and the down-regulation of VEGF gene expression. Cancer. 2004 Jan 1;100(1):201-10.
  60. Yang SH, Lin JK, Chen WS, et al. Anti-angiogenic effect of silymarin on colon cancer LoVo cell line. J Surg Res. 2003 Jul;113(1):133-8.
  61. Vallejo R, de Leon-Casasola O, Benyamin R. Opioid therapy and immunosuppression: a review. Am J Ther. 2004 Sep;11(5):354-65.
  62. Melamed R, Bar-Yosef S, Shakhar G, et al. Suppression of natural killer cell activity and promotion of tumor metastasis by ketamine, thiopental, and halothane, but not by propofol: mediating mechanisms and prophylactic measures. AnesthAnalg. 2003 Nov;97(5):1331-9.
  63. Gupta K, Kshirsagar S, Chang L, et al. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res. 2002 Aug 1;62(15):4491-8.
  64. Bar-Yosef S, Melamed R, Page GG, et al. Attenuation of the tumor-promoting effect of surgery by spinal blockade in rats. Anesthesiology. 2001 Jun;94(6):1066-73.
  65. Koltun WA, Bloomer MM, Tilberg AF, et al. Awake epidural anesthesia is associated with improved natural killer cell cytotoxicity and a reduced stress response. Am J Surg. 1996 Jan;171(1):68-72.
  66. Coveney E, Weltz CR, Greengrass R, et al. Use of paravertebral block anesthesia in the surgical management of breast cancer: experience in 156 cases. Ann Surg. 1998 Apr;227(4):496-501.
  67. Liu Z, Gao F, Tian Y. Effects of morphine, fentanyl and tramadol on human immune response. J HuazhongUnivSciTechnolog Med Sci. 2006;26(4):478-81.
  68. Gaspani L, Bianchi M, Limiroli E, et al. The analgesic drug tramadol prevents the effect of surgery on natural killer cell activity and metastatic colonization in rats. J Neuroimmunol. 2002 Aug;129(1-2):18-24.
  69. Lacy AM, Garcia-ValdecasasJC, Delgado S, et al. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet. 2002 Jun 29;359(9325):2224-9.
  70. Lacy AM, Delgado S, Castells A, et al. The long-term results of a randomized clinical trial of laparoscopy-assisted versus open surgery for colon cancer. Ann Surg. 2008 Jul;248(1):1-7.
  71. Kaseda S, Aoki T, Hangai N, et al. Better pulmonary function and prognosis with video-assisted thoracic surgery than with thoracotomy. Ann Thorac Surg. 2000 Nov;70(5):1644-6.
  72. Mahtabifard A, DeArmond DT, Fuller CB, et al. Video-assisted thoracoscopic surgery lobectomy for stage I lung cancer. ThoracSurgClin. 2007 May;17(2):223-31.
  73. Tepper J, KrasnaMJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J ClinOncol. 2008 Mar 1;26(7):1086-92.
  74. Cunningham D, AllumWH, StenningSP, et al. Perioperative chemotherapy versus surgery alone for resectablegastroesophageal cancer. N Engl J Med. 2006 Jul 6;355(1):11-20.
  75. Kim S, Lim DH, Lee J, et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J RadiatOncolBiol Phys. 2005 Dec 1;63(5):1279-85.
  76. Baigrie RJ, Lamont PM, Kwiatkowski D, et al. Systemic cytokine response after major surgery. Br J Surg. 1992 Aug;79(8):757-60.
  77. Wu FP, Sietses C, von Blomberg BM, et al. Systemic and peritoneal inflammatory response after laparoscopic or conventional colon resection in cancer patients: a prospective, randomized trial. Dis Colon Rectum. 2003 Feb;46(2):147-55.
  78. Volk T, Dopfmer UR, Schmutzler M, et al. Stress induced IL-10 does not seem to be essential for early monocyte deactivation following cardiac surgery. Cytokine. 2003 Dec 21;24(6):237-43.
  79. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998 May 29;93(5):705-16.
  80. Chu J, Lloyd FL, Trifan OC, et al. Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer. Mol Cancer Ther. 2003 Jan;2(1):1-7.
  81. Kakiuchi Y, Tsuji S, Tsujii M, et al. Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis. Cancer Res. 2002 Mar 1;62(5):1567-72.
  82. Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 1999 Mar 1;59(5):987-90.
  83. Chan G, Boyle JO, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 1999 Mar 1;59(5):991-4.
  84. Soumaoro LT, Uetake H, Higuchi T, et al. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res. 2004 Dec 15;10(24):8465-71.
  85. Yuan A, Yu CJ, Shun CT, et al. Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients. Int J Cancer. 2005 Jul 1;115(4):545-55.
  86. Edelman MJ, Watson D, Wang X, et al. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy –Cancer and Leukemia Group B Trial 30203. J ClinOncol. 2008 Feb 20;26(6):848-55.
  87. Pruthi RS, Derksen JE, Moore D, et al. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2172-7.
  88. Tester WJ, Valsecchi M, Pomerantz, S, et al. Reduced risk of bone metastases in breast cancer patients treated with Cox-2 inhibitors. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31561. Accessed March 27, 2012.
  89. Harris RE, Beebe-Donk J, Doss H, et al. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockage (review). Oncol Rep. 2005 Apr;13(4):559-83.
  90. Peng G, Dixon DA, MugaSJ, et al. Green tea polyphenol (-)-epigallocatechin-3-gallate inhibits cyclooxygenase-2 expression in colon carcinogenesis. MolCarcinog. 2006 May;45(5):309-19.
  91. Subbaramaiah K, Michaluart P, Chung WJ, et al. Resveratrol inhibits cyclooxygenase-2 transcription in human mammary epithelial cells. Ann NY Acad Sci. 1999;889:214-23.
  92. Subbaramaiah K, Chung WJ, Michaluart P, et al. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem. 1998 Aug 21;273(34):21875-82.
  93. Horia E, Watkins BA. Complementary actions of docosahexaenoic acid and genistein on COX-2, PGE2 and invasiveness in MDA-MB-231 breast cancer cells. Carcinogenesis. 2007 Apr;28(4):809-15.
  94. O’Leary KA, de Pascual-Tereasa S, Needs PW, et al. Effect of flavonoids and vitamin E on cyclooxygenase-2 (COX-2) transcription. Mutat Res. 2004 Jul 13;551(1-2):245-54.
  95. Hwang D, Fischer NH, Jang BC, et al. Inhibition of the expression of inducible cyclooxygenase and proinflammatory cytokines by sesquiterpene lactones in macrophages correlates with the inhibition of MAP kinases. BiochemBiophys Res Commun. 1996 Sep 24;226(3):810-8.
  96. Ali M. Mechanism by which garlic (Allium sativum) inhibits cyclooxygenase activity. Effect of raw versus boiled garlic extract on the synthesis of prostanoids. Prostaglandins LeukotEssent Fatty Acids. 1995 Dec;53(6):397-400.
  97. Ramakrishnan G, Elinos-Baez CM, Jagan S, et al. Silymarindownregulates COX-2 expression and attenuates hyperlipidemia during NDEA-induced rat hepatocellular carcinoma. Mol Cell Biochem. 2008 Jun;313(1-2):53-61.